|Dr. Ron Cohen||Founder, CEO, Pres & Director||827.95k||N/A||1956|
|Mr. David Lawrence||CTO, Chief of Bus. Operations & Principal Accounting Officer||480.9k||N/A||1958|
|Ms. Jane Wasman||Consultant||1.85M||N/A||1956|
|Ms. Lauren M. Sabella||Chief Commercial Officer||490.07k||N/A||1961|
|Dr. Burkhard Blank||Chief Medical Officer and Head of R&D||662.5k||N/A||1955|
Acorda Therapeutics, Inc., a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in patients with multiple sclerosis (MS); and Selincro, an orally administered drug for the treatment of alcohol dependence in Europe. It also markets Ampyra as Fampyra in Europe, Asia, and the Americas. In addition, the company develops Inbrija for the treatment of OFF periods in Parkinson's disease and ARCUS product for the treatment of acute migraine. Further, it develops rHIgM22, which has completed Phase I clinical trial for the treatment of MS; and Cimaglermin alfa that is in Phase Ib clinical trial for heart failure patients. The company has collaboration and license agreement with Biogen Inc. for the development and commercialization of Ampyra. Acorda Therapeutics, Inc. was founded in 1995 and is headquartered in Ardsley, New York.
Acorda Therapeutics, Inc.’s ISS Governance QualityScore as of December 8, 2019 is 6. The pillar scores are Audit: 1; Board: 6; Shareholder Rights: 7; Compensation: 6.